Results 51 to 60 of about 27,650 (185)

Immune Complexes Shape the Pathogenicity of Autoantibodies in Systemic Autoimmune Diseases: Insights From an FcγRIIIA‐Reporter Assay

Arthritis &Rheumatology, EarlyView.
Objective Immune complexes (ICs), formed by autoantigen and autoantibody, play a pathogenic role in systemic autoimmune diseases through stimulation of Fcγ receptors (FcγR). However, studies investigating bioactivity of circulating ICs across various diseases remain limited.
Koji Suzuki, Masaru Takeshita, Yuki Imai, Hiroyuki Fukui, Kazunori Furuhashi, Kotaro Matsumoto, Jun Kikuchi, Keiko Yoshimoto, Yuko Kaneko   +8 more
wiley   +1 more source

Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation

Respiratory Research, 2009
Severe pulmonary arterial hypertension, whether idiopathic or secondary, is characterized by structural alterations of microscopically small pulmonary arterioles.
Sakao Seiichiro, Tatsumi Koichiro, Voelkel Norbert F   +2 more
doaj   +1 more source

High geographic prevalence of pulmonary artery hypertension: associations with ethnicity, drug use, and altitude

Pulmonary Circulation, 2020
While estimates of pulmonary arterial hypertension incidence and prevalence commonly range from 1–3/million and 15–25/million, respectively, clinical experience at our institution suggested much higher rates.
Jason Dubroff, Lana Melendres, Yan Lin, Daniel Raley Beene, Loren Ketai   +4 more
doaj   +1 more source

Hypoxemia during sleep and overnight rostral fluid shift in pulmonary arterial hypertension: a pilot study

Pulmonary Circulation, 2021
Sleep-related breathing disorders, including sleep apnea and hypoxemia during sleep, are common in pulmonary arterial hypertension, but the underlying mechanisms remain unknown.
Etienne-Marie Jutant, David Montani, Caroline Sattler, Sven Günther, Olivier Sitbon, Gilles Garcia, Isabelle Arnulf, Marc Humbert, Thomas Similowski, Stefania Redolfi   +9 more
doaj   +1 more source

Pulmonary Arteriopathy and Idiopathic Pulmonary Arterial Hypertension in Six Dogs [PDF]

Veterinary Pathology, 2006
Pulmonary arteriopathy (PA) is the pathologic hallmark in human medicine of diffuse constrictive (medial and intimal remodeling) or multifocal complex (plexiform and dilatative lesions) arterial lesions, or both, that lead to irreversible obliteration of the arterial lumen.
Zabka, T., Campbell, F. E., Wilson, D.
openaire   +5 more sources

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source

Epistatic interactions in idiopathic pulmonary arterial hypertension

Indian Journal of Human Genetics, 2012
Idiopathic pulmonary arterial hypertension (IPAH) is a poorly understood complex disorder, which results in progressive remodeling of the pulmonary artery that ultimately leads to right ventricular failure. A two-hit hypothesis has been implicated in pathogenesis of IPAH, according to which the vascular abnormalities characteristic of PAH are triggered
Vadapalli, Shivani, Satyanarayana, M.L., Chaitra, K.L., Rani, H. Surekh, Sastry, B.K.S., Nallari, Pratibha   +5 more
openaire   +3 more sources

Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men.
Johannes Nagelschmitz, Soundos Saleh, Sandra Ligges, Melanie Seidel‐Greven, Eva Becker‐Pelster, Sylvia M. Nikkho, Stefanie Boxnick, Wolfgang Timmer   +7 more
wiley   +1 more source

Twelve-Year Survival in a Patient With Systemic Sclerosis–Associated Pulmonary Arterial Hypertension on Nifedipine Monotherapy

Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 2019
Pulmonary arterial hypertension is a progressive vascular disease with a high mortality rate without proper therapy. Identification of the appropriate treatment for each patient is critical in regard to adverse effects, health care costs, ease of ...
Scott A. Helgeson, MD, Cher Y. Enderby, PharmD, RPh, John E. Moss, MD, Jennifer M. Gass, PhD, Tonya K. Zeiger, RRT, Charles D. Burger, MD   +5 more
doaj   +1 more source

A Novel Speckle-Tracking Echocardiography Derived Parameter That Predicts Clinical Worsening in Children with Pulmonary Arterial Hypertension

Applied Sciences, 2022
Pulmonary arterial hypertension is a severe, progressive disease in children, that causes right ventricular dysfunction over time. Tissue motion annular displacement is a novel speckle-tracking derived echocardiographic parameter used in assessing ...
Iolanda Muntean, Mihaela Melinte, Amalia Făgărășan, Carmen Corina Șuteu, Rodica Togănel   +4 more
doaj   +1 more source